Legato Capital Management LLC Purchases 125,525 Shares of Bioventus Inc. $BVS

Legato Capital Management LLC boosted its position in Bioventus Inc. (NASDAQ:BVS) by 1,042.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 137,562 shares of the company’s stock after acquiring an additional 125,525 shares during the period. Legato Capital Management LLC’s holdings in Bioventus were worth $1,023,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Covestor Ltd boosted its holdings in Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after buying an additional 2,176 shares during the last quarter. Prelude Capital Management LLC bought a new position in shares of Bioventus during the 3rd quarter valued at about $74,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Bioventus during the 3rd quarter valued at about $78,000. SG Americas Securities LLC acquired a new stake in Bioventus in the 4th quarter valued at approximately $80,000. Finally, Truist Financial Corp acquired a new stake in Bioventus in the 4th quarter valued at approximately $93,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Price Performance

NASDAQ:BVS opened at $9.28 on Tuesday. The firm has a market capitalization of $775.25 million, a price-to-earnings ratio of 22.63, a price-to-earnings-growth ratio of 1.18 and a beta of 0.72. Bioventus Inc. has a twelve month low of $5.81 and a twelve month high of $11.25. The stock’s 50 day moving average price is $9.67 and its two-hundred day moving average price is $8.50. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts expect that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

BVS has been the topic of a number of recent research reports. CJS Securities initiated coverage on Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price on the stock. Barrington Research reissued an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a research report on Friday. Craig Hallum lifted their target price on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Finally, Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Bioventus has a consensus rating of “Buy” and an average price target of $14.00.

Insider Buying and Selling at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. The trade was a 21.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 33.00% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.